Clinical Trials Browser

Phase 1 × Neoplasms × ridaforolimus × Clear all

NCT00694083 2024-05-21

Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)

Phase 1 Completed

Neoplasms

NCT01380184 2019-04-19

MK-8669-059

Phase 1 Completed

15 enrolled 15 charts

Neoplasms, Recurrence

NCT01243762 2018-08-16

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Phase 1 Terminated

47 enrolled 12 charts

GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT00060632 2015-08-27

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Phase 1 Completed

LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Neoplasms

NCT00060645 2015-08-27

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Phase 1 Completed

LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Neoplasms

NCT00288431 2015-07-22

Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)

Phase 1 Completed

Neoplasms, Sarcoma

NCT00112372 2015-02-12

Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)

Phase 1 Completed

Neoplasm Metastasis, Neoplasms, Recurrence